BIOGEN for BIOGEN
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2022 | $900,000 | Replaced |
| 2nd Quarter - Amendment | Nov 8, 2022 | $940,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR | — |
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| TYLER HANSON | — |
| DANIEL HARDER | — |
| ALI LAKHANI New | — |
Medicare/Medicaid MMM
Discussions regarding coverage, coding, and reimbursement issues Policy proposals related to Medicare Part D and patient cost-sharing HHS drug policy issues and regulatory policy issues Draft National Coverage Determination on Alzheimer's treatments
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR | — |
| AMY DEMSKE | — |
| DANIEL HARDER | — |
Taxation/Internal Revenue Code TAX
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) International tax issues, including Pillar 1 and Pillar 2
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL HARDER | — |
Pharmacy PHA
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| DANIEL HARDER | — |
Copyright/Patent/Trademark CPT
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL HARDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.